RETRACTED ARTICLE: Prophylactic antiemetic therapy with granisetron-droperidol combination in patients undergoing laparoscopic cholecystectomy

  • Yoshitaka Fujii
  • Yuhji Saitoh
  • Hiroyoshi Tanaka
  • Hidenori Toyooka
Reports of Investigation



A relatively high incidence of postoperative nausea and vomiting (PONV) occurs in patients undergoing laparoscopic cholecystectomy. This study was undertaken to compare the efficacy of granisetron-droperidol combination with each drug alone for the prevention of PONV after laparoscopic cholecystectomy.


In a randomized, double-blind manner, 150 female inpatients received 3 mg granisetron (Group G), 1.25 mg droperidol (Group D) or 3 mg granisetron plus 1.25 mg droperidol (Group GD) (n = 50 for each)iv immediately before the induction of anaesthesia. The same standard general anaesthetic technique, which consisted of isoflurane and nitrous oxide in oxygen, was used. Nausea, vomiting and safety assessments were performed continuously during the first 24 hr after anaesthesia.


Complete response, defined as no PONV and no administration of rescue antiemetic medication, was 86% in Group G, 64% in Group D and 98% in Group GD (P = 0.03 vs Group G,P = 0.001 vs Group D). No clinically adverse events were observed in any group.


Granisetron-droperidol combination is more effective than each antiemetic alone in the prevention of PONV after laparoscopic cholecystectomy.



Des nausées et des vomissements post opératoires (NVPO) surviennent chez des patients subissant une cholécystectomie laparoscopique, selon une incidence relativement élevée. La présente étude a été entreprise pour comparer l’efficacité de la combinaison de granisétron-dropéridol et de chaque médicament employé seul afin de prévenir les NVPO à la suite d’une cholécystectomie laparoscopique.


Dans une étude randomisée, en double insu, 150 patientes ont reçu 3 mg de granisétron (Groupe G), 1,25 mg de dropéridol (Groupe D) ou 3 mg de granisétron plus 1,25 mg de dropéridol IV (Groupe GD) (n = 50 pour chacun) immédiatement avant l’induction de l’anesthésie. On a utilisé pour toutes les patientes la même technique traditionnelle d’anesthésie générale qui comprend l’emploi de l’isoflurane et de protoxyde d’azote dans l’oxygène. L’évaluation des nausées, des vomissements et des effets secondaires a été réalisée de façon continue pendant les 24 premières heures suivant l’anesthésie.


La réponse complète, définie comme l’absence de NVPO et d’administration d’antiémétique correctif, était de 86 % dans le Groupe G, 64 % dans le Groupe D et de 98 % dans le groupe GD (P = 0,03 vs Groupe G,P = 0,001 vs Groupe D). Aucune réaction clinique défavorable n’a été observée dans les groupes.


La combinaison de granisétron-dropéridol est plus efficace que chaque antiémétique employé seul dans la prévention des NVPO après une cholécystectomie laparoscopique.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stanton JM. Anaesthesia for laparoscopic cholecystectomy (Letter). Anaesthesia 1991; 46: 317.PubMedCrossRefGoogle Scholar
  2. 2.
    Iitomi T, Toriumi S, Kondo A, Akazawa T, Nakahara T. Incidence of nausea and vomiting after cholecystectomy performed via laparotomy or laparoscopy. (Japanese) Masui 1995; 44: 1627–31.PubMedGoogle Scholar
  3. 3.
    Fujii Y, Tanaka H, Toyooka H. Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy. Can J Anaesth 1997; 44: 396–400.PubMedCrossRefGoogle Scholar
  4. 4.
    Rowbotham DJ. Current management of postoperative nausea and vomiting. Br J Anaesth 1992; 69: 46S-59S.PubMedCrossRefGoogle Scholar
  5. 5.
    McKenzie R, Uy NTL, Riley TJ, Hamilton DL. Droperidol/ondansetron combination controls nausea and vomiting after tubal banding. Anesth Analg 1996; 83: 1218–22.PubMedGoogle Scholar
  6. 6.
    Watcha MF, White PF. Postoperative nausea and vomiting. Its etiology, treatment, and prevention. Anesthesiology 1992; 77: 162–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Bermudez J, Boyle FA, Miner WD, Sanger GJ. The antiemetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 1988; 58: 644–50.PubMedCrossRefGoogle Scholar
  8. 8.
    Carmichael J, Cantwell BMJ, Edwards CM, et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response. Cancer Chemother Pharmacol 1989; 24: 45–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Fume H, Oota K, Taguchi T, Niitani H. Clinical evaluation of granisetron against nausea and vomiting induced by anticancer drugs. (I) Optimal dose-finding study. (Japanese) J Clin Ther Med 1990; 6(Suppl 5): 49–6l.Google Scholar
  10. 10.
    Korttila K, Kauste A, Auvinen J. Comparison of domperidone, droperidol, and metoclopramide in the prevention and treatment of nausea and vomiting after balanced general anesthesia. Anesth Analg 1979; 58: 396–400.PubMedCrossRefGoogle Scholar
  11. 11.
    Cohen SE, Woods WA, Wyner J. Antiemetic efficacy of droperidol and metoclopramide. Anesthesiology 1984; 60: 67–9.PubMedCrossRefGoogle Scholar
  12. 12.
    White PF, Watcha MF. Are new drugs cost-effective for patients undergoing ambulatory surgery? (Editorial) Anesthesiology 1993; 78: 2–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Lerman J. Are antiemetics cost-effective for children (Editorial) Can J Anaesth 1995; 42: 263–6.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1998

Authors and Affiliations

  • Yoshitaka Fujii
    • 1
  • Yuhji Saitoh
    • 2
  • Hiroyoshi Tanaka
    • 3
  • Hidenori Toyooka
    • 1
  1. 1.Department of AnaesthesiologyUniversity of Tsukuba Institute of Clinical MedicineIbarakiJapan
  2. 2.Department of Anaesthesiology and Critical Care MedicineTokyo Medical and Dental University School of MedicineTokyoJapan
  3. 3.Department of AnaesthesiologyToride Kyodo General HospitalIbarakiJapan

Personalised recommendations